Crescent Biopharma Inc. (CBIO) carries a Roarable Rating of D (Sell) with 44/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.
Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer
20D Institutional Volume Accumulation (±12.5% realized swing band)
Altman Z-Score 6.36 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 3/9
Dilution Drag (+2.48% YoY Shares) & executive Form 4 sales trim 16 pts from alignment
While CBIO currently carries a cautious 44/100 (D) rating due to Insider Conviction & Share Dilution (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.
Established market leader in Health Care with deep daily trading liquidity.
Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($15.62) and Max Pain ($14.77) forces dealer call-delta covering toward $28.78.
Forensic Repair Trigger: Halting share dilution (Dilution Drag (+2.48% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.
Crescent Biopharma Inc. (CBIO) surged +4.22% to $14.07, trading at 29% of its 52-week range ($8.72 – $27.41). Stretched risk/reward at current multiples (-35% return on capital) under elevated 10-year interest-rate pressure.
HC Wainwright & Co. analyst Mitchell S. Kapoor reiterates Crescent Biopharma (NASDAQ:CBIO) with a Buy and maintains $36 price target.
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
vs. +6.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
No active Ellis Vennor swing setup published on CBIO today. View full Setup Ledger →
No direct multi-tier Butterfly edges indexed yet for CBIO. Explore sector supply chains on /butterfly.
Across 1016 tracked Health Care securities in the Roarable RQD universe, Crescent Biopharma Inc. (CBIO) ranks #505 by composite RQD confidence (44/100, grade D) and #439 by equity capitalization ($522.6M). Within this direct 5-issuer industry benchmark cohort, CBIO leads on earnings valuation at N/A trailing P/E, while ARVN leads on capital efficiency and profitability with -32.1% ROIC and — gross margin. OCS currently holds the highest overall quantitative score in the immediate peer group at 58/100 (D+) compared with CBIO at 44/100 (D).
| Ticker / Company | Roarable Grade | RQD Score | Trailing P/E | Gross Margin | ROIC | 1D Change | Market Cap | Head-to-Head |
|---|---|---|---|---|---|---|---|---|
| CBIO
ACTIVE
Crescent Biopharma Inc. | D | 44/100 | — | — | -35.0% | +4.22% | $522.6M | Benchmark Subject |
| ARVN Arvinas Inc. | D- | 37/100 | — | — | -32.1% | +3.95% | $516.6M | /arvn-vs-cbio → |
| DMAC DiaMedica Therapeutics Inc. | E | 34/100 | — | — | -35.0% | -3.05% | $513.4M | /dmac-vs-cbio → |
| INDP Indaptus Therapeutics Inc. | D- | 36/100 | — | — | -35.0% | +0.30% | $513.0M | /indp-vs-cbio → |
| OCS Oculis Holding AG | D+ | 58/100 | — | — | — | +3.26% | $507.5M | /ocs-vs-cbio → |
In its most recent audited fiscal period (FY2025, filed 2025-12-31), Crescent Biopharma Inc. (CBIO) reported GAAP revenue of $10.8M (N/A vs. FY2024 revenue of $0 ) , GAAP net income of $153.9K, operating cash flow of -$71.5M, and free cash flow of -$72.5M (-132.9% YoY). On the balance sheet, CBIO closed FY2025 with $240.3M in total assets against $0 in total debt (Altman Z-Score: 6.36, Piotroski F-Score: 3/9).
| Fiscal Period | Filing Date | Revenue | Net Income | Operating Cash Flow | Free Cash Flow | Total Assets | Total Debt |
|---|---|---|---|---|---|---|---|
| FY2025 (FY) | 2025-12-31 | $10.8M | $153.9K | -$71.5M | -$72.5M | $240.3M | — |
| FY2024 (FY) | 2024-12-31 | $0 | $37.9K | -$31.1M | -$31.1M | $35.6M | — |
| FY2023 (FY) | 2023-12-31 | $0 | $36.9K | -$34.9M | -$34.9M | — | — |
As of 2026-11-01, Crescent Biopharma Inc. (NASDAQ: CBIO) is rated D (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 44/100 at a spot price of $14.07 (+4.22% 1D, market cap $522.6M). Pillar breakdown: Fundamental Cash Engine 5/20, Institutional 13F & Options Flow 13/20, Executive Insider Alignment 13/20, FRED Macro Regime Fit 10/20, and SEC Balance-Sheet Forensics 3/20. Across 1016 tracked Health Care issuers, CBIO ranks #505 in composite RQD confidence.
Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), CBIO carries a Roarable D (44/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, ARVN (Arvinas Inc.) holds a D- grade (37/100 RQD, P/E N/A, ROIC -32.1%, cap $516.6M) and DMAC (DiaMedica Therapeutics Inc.) posts a E grade (34/100 RQD, P/E N/A, ROIC -35.0%, cap $513.4M). Among the 5-stock peer group, CBIO leads on earnings multiple (N/A) while ARVN leads on capital efficiency (-32.1% ROIC).
Per CBIO's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001253689), Crescent Biopharma Inc. generated $10.8M in revenue, $153.9K in net income, and -$72.5M in free cash flow against $240.3M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.
CBIO last traded at $14.07 (+4.22% on volume of 378,034 shares), positioning the stock -9.92% below its 50-day simple moving average ($15.62) and -11.45% below its 200-day simple moving average ($15.89). Across its 52-week range of $8.72 to $27.41, CBIO sits at the 28.6% percentile with a 14-day RSI of 46.1 (NEUTRAL RANGE) and an implied next-earnings move of ±12.5% ($12.31 to $15.83).
Why CBIO Stock surged +4.22% Today — RQD Quant Desk Flash. Stretched risk/reward at current multiples (-35% return on capital) under elevated 10-year interest-rate pressure.
To protect compute speed and zero-delay Cboe BZX data quality for active members, our current $9.95/month Roarable Pro cohort is 100% full. Join the priority waiting list below and we will notify you the moment the next batch of Pro accounts opens (and lock in your $9.95/mo rate).
Link your personal ChatGPT, Claude Desktop, or Cursor via Roarable's Model Context Protocol (`mcp.roarable.com`) to query all 5,289 stocks, inspect Butterfly supply chains, and trade your `$100K Arena` account.
Interrogate SEC 10-K/10-Q filings on demand and ask custom ticker, valuation, or short-thesis questions directly to any of our 8 specialized AI Quant Analysts.
Command our AI agents to sort and sift 5,289 stocks by custom formulas, follow multi-indicator technical & cash-flow setups, and send you instant Email/SMS breakout & downgrade alerts.
Unlock sub-second Cboe BZX streaming quotes, pre-market/after-hours delta scanners, instant SEC Form 4 insider cluster alerts, and unlimited portfolio stress-testing.
All 8 Roarable Analysts (Mara Quenwick, Devon Kess, Gideon Vane, Eliott Vance, Sorel Thorne, Corin Hale, Tessa Rane, and Felix Orven) are proprietary AI Quant Analysts and automated algorithmic specialists — not human financial advisors, fiduciaries, or registered broker-dealers. While one-to-many daily stock ratings and briefings are free, custom 1-on-1 Q&A, custom AI sifting/indicator alert agents, and personal ChatGPT/Claude MCP connections consume dedicated per-user compute and require a $9.95/month Roarable Pro membership. All AI outputs are for educational and research purposes only and never constitute individualized investment advice.
Enter your Google email below for instant 1-step account activation, daily A–E stock rating alerts, and immediate access to your $100,000.00 Paper Trading Arena account.